Vistagen TherapeuticsVTGN +5.14%40 PB Ratio is 0.74 as of Jun. 24, 2026, which is 58% below its 10-year median of 1.75. GuruFocus rates VTGN with a GF Score™ of 40/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Vistagen Therapeutics ranks better than 91.08% on this metric.
The historical rank and industry rank for Vistagen Therapeutics's PB Ratio or its related term are showing as below:
VTGN'
s PB Ratio Range Over the Past 10 Years
Min: 0.39 Med: 1.75 Max: 30.94
Current: 0.74
During the past 13 years, Vistagen Therapeutics's highest PB Ratio was 30.94. The lowest was 0.39. And the median was 1.75.
VTGN's PB Ratio is ranked better than 91.08% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs VTGN: 0.74
During the past 12 months, Vistagen Therapeutics's average Book Value Per Share Growth Rate was -63.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -39.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vistagen Therapeutics was 53.60% per year. The lowest was -1736.40% per year. And the median was -21.95% per year.
Back to Basics: PB Ratio
Vistagen Therapeutics (NAS:VTGN) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vistagen Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vistagen Therapeutics (VTGN) has a PB Ratio of 0.74 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vistagen Therapeutics and its competitors. This is 58% below median its historical median of 1.75. Over the past decade, Vistagen Therapeutics' PB Ratio has ranged from 0.39 to 30.94. According to the industry distribution chart, Vistagen Therapeutics ranks #110 out of 1233 companies in the Biotechnology industry, placing it in the top 8.9%.
Is Vistagen Therapeutics' PB Ratio too high?
Vistagen Therapeutics' current PB Ratio of 0.74 is 58% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 30.94. The Biotechnology industry median PB Ratio is 2.83. Vistagen Therapeutics' value of 0.74 is 73.9% below this industry median. Based on the distribution chart, Vistagen Therapeutics ranks #110 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' PB Ratio compare to PLUR and PTN?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #110 out of 1233 companies for PB Ratio. This places Vistagen Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.83. Vistagen Therapeutics' value of 0.74 is 73.9% below this benchmark. Historically, Vistagen Therapeutics' own PB Ratio has ranged from 0.39 to 30.94 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 2.83, Vistagen Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistagen Therapeutics's current PB Ratio of 0.74 is 73.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vistagen Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistagen Therapeutics's current PB Ratio is 0.74, which is 58% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vistagen Therapeutics (VTGN) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.67 — trading 69.7% below its estimated fair value. The current PB Ratio is 0.74, which is 58% below median its 10-year median of 1.75 and 73.9% below the Biotechnology industry median of 2.83. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current PB Ratio is 0.74 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of $0.67 is trading 69.7% below its estimated GF Value™ of $2.20.
GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.
Key valuation signals for VTGN:
PB Ratio: 0.74 (58% below median its 10-year median of 1.75)
GF Value™: $2.20 vs. price of $0.67 (69.7% below fair value)
Industry Position: 73.9% below the Biotechnology median (#110 of 1233)
No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score
Get the complete analysis for VTGN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTGN has been successfully added to your 
